Development of a novel treatment for prostate cancer using humanized HGF SCID mice

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K09580
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56030:Urology-related
• Research Institution: University of Fukui (2022); University of Miyazaki (2020-2021)
• Principal Investigator: Terada Naoki 福井大学, 学術研究院医学系部門, 教授 (60636637)
• Co-Investigator(Kenkyū-buntansha): 賀本 敏行 宮崎大学, 医学部, 教授 (00281098) ; 向井 尚一郎 宮崎大学, 医学部, 准教授 (10315369)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 前立腺癌

Outline of Final Research Achievements

Newly established humanized HGF-producing human HGF SKID mice were transplanted with KUCaP, a previously established prostate cancer patient derived xenograft (PDX), to develop a novel HGF-MET pathway targeting treatment for metastatic prostate cancer. However, it was difficult to breed Humanaized HGF SKID mice. Therefore, using 786-O-HAI-2, a renal cell carcinoma cell line that expresses HAI-2 upon administration of doxycycline, we investigated that the combined use of MET inhibitors with the enhancement of HAI-2 expression ihibit the cell proliferation. These results might be connect to future research on prostate cancer.

Free Research Field

泌尿器科癌

Academic Significance and Societal Importance of the Research Achievements

骨転移を有する前立腺癌患者の予後は不良であり、新たな骨転移治療法の開発は急務である。METは前立腺癌骨転移で発現が高く、骨転移を有する前立腺癌患者に対するMET阻害薬の有効性が報告されたが、副作用の多さもあり、現時点では臨床での使用には至っていない。今後、前立腺癌におけるMET-HGFパスウェイを標的とした治療が開発されれば、骨転移を有する予後不良な前立腺癌患者に対して多大なる恩恵を与えることができ、社会的意義が高い。